München (ots) - Ab sofort verstärken Christiane Ritter, Tim Jungblut und Sebastian Schütze das Team von ...
Jan Van Ruymbeke to become new CEO of Daiichi Sankyo Europe
The Belgian executive will replace Reinhard Bauer in October
Munich (ots) - Jan Van Ruymbeke, 53, will become the new Chief Executive Officer of Daiichi Sankyo Europe this autumn. The native of Belgium will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharmaceutical company in October. Until the end of June, he had been the Executive Vice President at Grünenthal who oversaw the company's business in Latin America.
After studying medicine at the Catholic University of Leuven, he worked for several years as a general practitioner and a medical consultant. He then began his pharmaceutical career. Initially, he worked for Cilag Belgien before accepting a position with Janssen Pharmaceutical, where he directed the indication areas for infectious diseases and dermatology. In 1996, he became General Manager of Janssen-Cilag Hungary. Four years later, he assumed the position of Executive Director Pharma & Country President at Novartis South Africa.
In 2005, Van Ruymbeke joined Grünenthal, where he served as Head of Global Brand Management. Two years later, he was appointed Managing Director of the German pharmaceutical company's Spanish subsidiary. He later became the Managing Director responsible for Spain and Portugal. In July 2010, he was named Executive Vice President of the Latin America strategic business unit. As part of these responsibilities, he joined the Group Operating Committee at Grünenthal Group.
"We are really pleased that we were able to hire Jan Van Ruymbeke to be the next CEO of Daiichi Sankyo Europe," the outgoing CEO Bauer said. "He has an excellent understanding of the pharmaceutical industry. Thanks to his extensive experience in many countries, he is the ideal candidate to lead Daiichi Sankyo Europe's internationally focused business." Van Ruymbeke is married and has three children. His hobbies include reading, travelling and tennis.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model", which will respond to market and customer diversity and optimize growth opportunities across the value chain.
The company's world headquarters are in Tokyo. Its European base is located in Munich. Daiichi Sankyo Europe has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany.
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of Daiichi Sankyo Europe GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, inclu¬ding the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. Daiichi Sankyo Europe GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
Dr. Thomas Portz
Head of Corporate Communications and Public Affairs
Tel. +49 89 7808468
Mobil: +49 172 8415904